Two-year results of a randomized, phase III comparative trial of telbivudine versus lamivudine in Chinese patients

Purpose The burden of chronic hepatitis B infection is high in China, where prevalence exceeds 7 %. This was a randomized, double-blinded, phase III study of the efficacy and safety of telbivudine and lamivudine treatment at 104 weeks in Chinese patients with chronic hepatitis B.